Janssen licenses Tipifarnib to EB Pharma

Posted on 29 December 2014

EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

EB Pharma is conducting clinical studies in patients infected with Hepatitis Delta Virus (HDV) and will assess the efficacy and tolerability of tipifarnib as a potential new therapy.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends